Enzalutamide may soon gain approval for men with nonmetastatic castration-resistant prostate cancer on the basis of results from the PROSPER study.

AUA 2012: Enzalutamide, an androgen-receptor signaling inhibitor, improves survival in postdocetaxel prostate cancer, according to a phase 3 study.

If criteria based on serum testosterone increase from baseline to Week 12 are met, the study will proceed to a 52-week randomized phase in which the effects of darolutamide (600 mg twice daily, n = 20 ...

Study Design: This interventional study is randomized and follows a parallel assignment model. It is double-blind, meaning neither participants nor the care providers, investigators, or outcome ...

The oral androgen receptor inhibitor enzalutamide significantly reduced the risk for prostate cancer progression or death compared with bicalutamide in patients with castration-resistant prostate ...

Enzalutamide (trade name: Xtandi) has been approved since December 2014 for men who have metastatic prostate cancer that is not susceptible to hormone-blocking therapy, who have no symptoms or ...

A new study by University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about ...

Enzalutamide monotherapy also delayed prostate-specific antigen (PSA) progression by 6 months versus AS alone (HR 0.71, 95% CI 0.53-0.97, P=0.03), they noted in JAMA Oncology. This study ...

Enzalutamide conferred small but statistically significant improvements in outcomes vs. abiraterone acetate for men with metastatic castration-resistant prostate cancer, according to retrospective ...

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: A multicenter randomized phase II trial (OCUU-CRPC study). Authors : ...